Z. Fay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Paul L. Kaufman et al.

Serial No.:

09/022,228

Group No.: 1614

Filed:

February 11, 1998

Examiner:

Entitled:

Cytoskeletal Active Agents for Glaucoma Therapy

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT OR PENDING APPLICATION

12

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Petitioners, Wisconsin Alumni Research Foundation and Yeda Research and Development Company are the owner of one-hundred percent (100%) interest in the instant application. The Assignments from the inventors of the application identified above were recorded in the U.S. Patent and Trademark Office at Reel 8049, Frame 0306 and Reel 8367, Frame 0152. Petitioners hereby disclaim except as provided below the terminal part of the statutory term of any patent granted on the application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173 of copending U.S. Patent No. 5,798,380, and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent be the same as the legal title to the above referenced application or patent, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioners do not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, in the event that U.S. Patent No. 5,798,380: expires for failure to pay a

09/23/1999 FPATTERS 00000002 081290 09022228

01 FC:148

110.00 CH

PATENT
Attorney Docket No. WARF-02915

maintenance fee; is held unenforceable; if found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321; has all claims cancelled by a reexamination certificate; is reissued; or is otherwise terminated prior to the expiration of its full statutory term.

The undersigned has reviewed all the evidentiary documents accompanying or referred to in the instant Terminal Disclaimer and it is certified to the best of the undersigned's knowledge and belief, title is in the Assignees identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Assignees.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: March 26, 1999

MEDLEN & CARROLL 220 Montgomery Street, Suite 2200 San Francisco, California 94104

KAMRIN T. MÁCKNIGH Registration No. 38,230

415/705-8410

DATE: 10-15-99	APPL. S.N.: 091 022, 228
TO EXAMINER: Z, Fax	ART UNIT:
M. MINTGOMERY ROOM/18/8	MAILROOM DATE 3-36-95
AFTER FINAL YESNONUMBER OF T.D(S). FILED	
The T.D. is PROPER and has been recorded. (See 14.23).	
[] The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below. (See 14.24).	
[] The recording fee of \$ has not been submitted nor is there any pre authorization in the application file to charge to a deposit account. (See 14.26.07)	
[] Application Examiner has not processed T.D. fee. (See fee authoriza	ation).
[] The T.D. does not satisfy Rule 321(b)(3) in that the person who has signed the T.D. has not stated his/her interest (and/or the extent of the interest of the business entity represented by the signature) in the application/patent. (See 14.26 and 14.26.01).	
[] The T.D. lacks the enforceable only during the common owership clause needed to overcome a double patenting rejection, Rule 321(c). (See 14.27, 14.27.01).	
[] It is directed to a particular claims(s), which is not acceptable since "the disclaimer must be of a terminal portion of the term of the entire patent to be granted". MPEP 1490. (See 14.26, 14.26.02).	
[] The person who signed the terminal disclaimer: [] has falled to state his/her capacity to sign for the business er [] is not recognized as an officer of the assignee, (See 14.29 a	
[] No documentary evidence of a chain of title from the original inventor(s) to assignee has been submitted, nor is the reet and frame specified as to where such evidence is recorded in the office. 37 CFR 3.73(b). (See 1(40 O.G. 72). <u>NOTE</u> : This documentary evidence or the specifying of the reel and frame may be found in the T.D. <u>or</u> in a seperate paper <u>submitted by applicant</u> . (See 14:30).	
[] No "statement" specifying that the evidentiary documents have been re knowledge and belief the title is in the assignee seeking to take action. 37 C	viewed and that, to the best of the assignee's FR 3.73(b). (See 1140 O.G. 72) (See 14.31).
[] The T.D. is not signed. (See 14.26, 14.26.3). or 14.26.03 if TD is not s	signed by all the owners.
[] Attorney not of record in oath/decl. or a seperate paper filed appointing	a new or associate attorney. (See 14.29.01).
[] The serial number of the application (or the number of the patent) which forms the basis for the double patenting is missing or incorrect. (See 14.32).	
[] The serial number of this application (or the number of the patent in ree or incorrect. (See 14.26, 14.26.04 or 14.26.05).	xam or reissue case(s) being disclaimed is missing
[] The period disclaimed is incorrect or not specified. (See 14.27, 14.27.2	or 14.27.3)(For Samples 14.27.04 and 14.27.05)
[] Other:	
[] Suggestion to request refund of \$ (See 14.35, 14.36).	,
[] EXAMINER NOTE: IF APPLICATION IS IN CONDITION FOR ALLOWANCE ANY OF THE ABOVE INFORMALTIES	
MAY BE FAXED IN TO THE GROUP	
FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIFICATES:	
 Sample of a 1D over a pending application and assignee Certificate (See 14.37). Sample of a TD over a prior patent and assignee Certificate (See 14.38). Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39) 	